Sopheon plc (“Sopheon” or “the Company”) announces that the Company has granted 20,970 options (“Options”) over ordinary shares of 20 pence each in the share capital of the Company (“Ordinary Shares”) to certain directors. These grants are part of a wider grant of 93,689 Options, primarily to executive and departmental managers and certain senior employees. Of the directors, Andrew Michuda has been granted 15,120 Options, and Arif Karimjee has been granted 5,850.
The Options granted will vest over 3 years, and are exercisable up to 10 years from the date of grant. The exercise price of the Options is 87.5 pence per share, being the mid-market closing price on AIM on 8 April 2016.
Following this grant, Andrew Michuda has 215,000 Options in total, and Arif Karimjee has 63,350. In addition, Andrew Michuda and Arif Karimjee each own 30,000 Ordinary Shares of the Company, and they (or persons connected with them) are invested in £45,000 and £27,000 respectively of the Company’s convertible loan stock.
For Further Information Contact:
|Barry Mence, (Chairman)||Sopheon plc||+ 44 (0) 1276 919 560|
|Arif Karimjee, (CFO)||Sopheon plc||+ 44 (0) 1276 919 560|
|Ed Frisby / Carl Holmes (Corporate Finance)||finnCap||+ 44 (0) 20 7220 0500|
|Mia Gardner (Corporate Broking)||finnCap|
Sopheon (LSE: SPE) partners with customers to provide complete enterprise innovation management solutions including software, expertise, and best practices, that enable them to achieve exceptional long-term revenue growth and profitability. Sopheon’s Accolade solution provides unique, fully-integrated coverage for the entire innovation management and new product development lifecycle, including strategic innovation planning, roadmapping, idea and concept development, process and project management, portfolio management and resource planning. Sopheon’s solutions have been implemented by over 200 customers with over 60,000 users in over 50 countries. Sopheon is listed on AIM, operated by the London Stock Exchange.